- Home
- GHRS vs COGT Comparison
GHRS vs COGT Comparison
Compare GHRS & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHRS
- COGT
- Stock Information
- Founded
- GHRS 2018
- COGT 2014
- Country
- GHRS Ireland
- COGT United States
- Employees
- GHRS N/A
- COGT N/A
- Industry
- GHRS Biotechnology: Pharmaceutical Preparations
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- GHRS Health Care
- COGT Health Care
- Exchange
- GHRS Nasdaq
- COGT Nasdaq
- Market Cap
- GHRS 868.7M
- COGT 1.0B
- IPO Year
- GHRS 2021
- COGT 2018
- Fundamental
- Price
- GHRS $12.51
- COGT $8.00
- Analyst Decision
- GHRS Strong Buy
- COGT Buy
- Analyst Count
- GHRS 3
- COGT 6
- Target Price
- GHRS $35.67
- COGT $14.17
- AVG Volume (30 Days)
- GHRS 1.1M
- COGT 1.3M
- Earning Date
- GHRS 03-07-2025
- COGT 03-04-2025
- Dividend Yield
- GHRS N/A
- COGT N/A
- EPS Growth
- GHRS N/A
- COGT N/A
- EPS
- GHRS N/A
- COGT N/A
- Revenue
- GHRS N/A
- COGT N/A
- Revenue This Year
- GHRS N/A
- COGT N/A
- Revenue Next Year
- GHRS N/A
- COGT N/A
- P/E Ratio
- GHRS N/A
- COGT N/A
- Revenue Growth
- GHRS N/A
- COGT N/A
- 52 Week Low
- GHRS $6.00
- COGT $5.73
- 52 Week High
- GHRS $20.50
- COGT $12.61
- Technical
- Relative Strength Index (RSI)
- GHRS 51.44
- COGT 41.50
- Support Level
- GHRS $13.50
- COGT $7.88
- Resistance Level
- GHRS $14.91
- COGT $8.37
- Average True Range (ATR)
- GHRS 1.58
- COGT 0.42
- MACD
- GHRS -0.22
- COGT -0.11
- Stochastic Oscillator
- GHRS 5.56
- COGT 5.85
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.